Neogen (NEOG) to Release Earnings on Wednesday

Neogen (NASDAQ:NEOG - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $225.27 million for the quarter. Neogen has set its FY 2025 guidance at EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its quarterly earnings results on Friday, January 10th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.12. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The firm had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. During the same period in the previous year, the business earned $0.11 EPS. The company's revenue was up .7% compared to the same quarter last year. On average, analysts expect Neogen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Neogen Stock Down 4.1 %

Shares of Neogen stock traded down $0.33 during trading hours on Friday, reaching $7.80. 6,550,986 shares of the company's stock were exchanged, compared to its average volume of 2,291,990. The stock has a market cap of $1.69 billion, a P/E ratio of -3.56 and a beta of 1.57. The company has a 50 day moving average of $9.80 and a two-hundred day moving average of $12.44. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33. Neogen has a fifty-two week low of $7.68 and a fifty-two week high of $18.58.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NEOG. Guggenheim began coverage on Neogen in a research note on Thursday, December 19th. They issued a "buy" rating and a $15.00 price target for the company. Piper Sandler reissued a "neutral" rating and issued a $13.00 target price (down from $16.50) on shares of Neogen in a research note on Tuesday, January 21st.

Insider Transactions at Neogen

In other Neogen news, CEO John Edward Adent purchased 23,035 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The shares were acquired at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the purchase, the chief executive officer now owns 269,164 shares in the company, valued at approximately $2,968,878.92. The trade was a 9.36 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO David H. Naemura purchased 14,800 shares of the business's stock in a transaction on Thursday, January 16th. The shares were acquired at an average cost of $11.11 per share, with a total value of $164,428.00. Following the acquisition, the chief financial officer now directly owns 61,434 shares in the company, valued at approximately $682,531.74. The trade was a 31.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.13% of the stock is owned by company insiders.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.